The Octamer 4 gene (Oct4) is a master pluripotency controller that has been detected in several types of tumors. Here, we examine the expression of Oct4 in human esophageal squamous cell carcinoma (ESCC). We found that punctate Oct4 protein was expressed in most (93.7%) ESCC samples but it was not observed in esophageal mucosa. Some ESCC cells had the capacity to form tumorospheres; those with an Oct4 + -rich cell phenotype had increased proliferation and Oct4 mRNA levels compared to those of differentiated cells in culture or xenograft tumors. The over-expression of Oct4 in ESCCs suggests that it is a potential target for ESCC therapy. Oct4 could be a useful tumor marker in an immunohistochemical panel designed to differentiate between ESCC and esophageal mucosa. Expression of Oct4 in tumorospheres might indicate the presence of a population of ECSCs and its expression in xenograft tumors suggests that Oct4 is also associated with tumor metastasis.
INTRODUCTION
Esophageal cancer (EC) is a lethal cancer with a poor prognosis (Jemal et al., 2008) ; the survival rate is only 15% at 5 years and remains less than 20-30% at 2 years even after surgical resection (Jemal et al., 2008) . Squamous cell adenocarcinoma is the most common type of malignant tumor in the esophagus. The prognosis for patients with esophageal squamous cell cancer (ESCC), which remains the most frequent cause of cancer-related deaths (Enzinger and Mayer, 2003) , is poor because of the high rate of local and distant metastases at the time of diagnosis. It has been suggested that only a fraction of tumor cells are responsible for tumor regrowth. Cancer cells are clonal in origin and might undergo processes similar to the self--renewal and differentiation of normal stem cells (Reya et al., 2001) . Multipotent cancer stem cells (CSC) might explain the histologic heterogeneity found in tumors (Gao, 2008) . Zhang et al. found esophageal cancer stem-like cells (CSLC) after establishing radioresistant esophageal carcinoma cell lines (Zhang et al., 2008) that expressed Octamer 4 (Oct4). This finding prompted us to examine Oct4 expression in ESCC tissues.
Oct4 is a member of the family of POU-domain transcription factors and its expression is normally confined to pluripotent cells of the developing embryo (Nichols et al., 1998) . However, Oct4 has been shown to be a master pluripotency controller that is expressed in neoplastic germ cells with pluripotent potential (Cheng et al., 2007; Looijenga et al., 2003) , including seminomas (Ezeh et al., 2005; Jones et al., 2004 ), embryonal carcinomas (Jones et al., 2004 and dysgerminomas (Cheng et al., 2004) . In adults, Oct4 protein expression in tumors has been observed in bladder cancer (Atlasi et al., 2007) , breast carcinoma (Ezeh et al., 2005) , oral squamous cell carcinoma (Chiou et al., 2008) and gastric cancer (Chen et al., 2009 ). Knockdown of Oct4 has been shown to arrest proliferation, resulting in the apoptosis of CSLCs (Hu et al., 2008) . With respect to the new CSC theory, the expression of such genes is potentially correlated with tumorigenesis and might affect some aspects of tumor behavior, such as tumor recurrence or resistance to therapies; therefore, we investigated the expression of Oct4 in ESCC and its potential role in ESCC therapy.
MATERIALS AND METHODS

Patients
This study was approved by the Medical Ethics Committee of Hubei Medical University. A total of 174 Chinese patients (95 males aged 42 ± 12 years; 69 females aged 45 ± 11 years; the age range of all patients 35-76 years) were enrolled in the study. All patients provided informed written consent.
Tissue array samples ESCC and esophageal mucosa (EM) array slides containing formalin-fixed, paraffin-embedded tissues were purchased from Shaanxi Chaoyin Biological Company (China). Each slide contained 153 tissue specimens obtained before any treatment of patients who underwent esophagectomy. The main indications were ESCC (stage I, n = 65; stage IIA, n = 29; stage IIB, n = 17; stage III, n = 9; stage IV, n = 7; total, n = 127) and EM (n = 26). The clinical staging was done according to the tumor-node metastasis classification system.
Tumorosphere culture ESCC fresh tissues were obtained within 30 min after surgical resection (stage I, n = 14; stageIIA, n = 4; stageIIB, n = 3; total n = 21), immediately washed in PBS containing 500 U/L penicillin G (Gibco, USA) and 500 mg/L streptomycin (Gibco, USA) to remove blood cells, cut with scissors into small pieces and digested overnight in DMEM/F12 supplemented with 0.5 mg/ml collagenase IV (Gibco, USA). The unsorted cells were diluted with serum-free medium (SFM; a mixture of DMEM-F12 containing 10 ng/ml fibroblasts and 20 ng/ml epidermal growth factors (Gibco, USA), 5 ng/ml insulin (Gibco, USA), 2.75 mg/ml transferrin (Gibco, USA), 2.75 ng/ml selenium (Insulin-Transferrin-Selenium solution, Gibco, USA), 10 5 U/L penicillin and 100 mg/L streptomycin). Cells were plated at a density of 5 × 10 5 live cells/100 mm plate at 37°C in a humidified 5% CO 2 atmosphere. Tumorospheres were dissociated every 7-10 days by incubation in nonenzymatic cell dissociation solution (Sigma, USA) for 2 min at 37°C and passaged at 1 × 10 3 cell/plate. Tumorosphere cells were induced to differentiate in stem cell medium by adding fetal calf serum (FCS, 10% v/v).
Immunohistochemical staining
Tissue samples were fixed in phosphate-buffered 10% formalin (pH 7.2), embedded in paraffin and 4 μm thick sections were cut. Tissue microarray sections were dewaxed in xylene and dehydrated in alcohol. Antigen retrieval was done by heating samples to 100°C for 10 min in 0.01 M sodium citrate buffer (pH 6.0). After three rinses in PBS (5 min each), the sections were immersed in 3% H 2 O 2 for 30 min to suppress endogenous peroxidase activity. After rinsing in PBS, the sections were incubated with normal mouse serum at 37°C for 15 min to block nonspecific antibody binding, followed by incubation with mouse monoclonal anti-human Nanog antibody (1:100 in PBS, Santa Cruz Biotechnology, USA) for 2 h at room temperature. After three washes in PBS (5 min each), the sections were incubated with biotinylated secondary antibody (Santa Cruz Biotechnology, USA) and then rinsed with PBS. After incubation (1 h at room temperature) in a solution containing streptavidin-HRP (Kangwei Century Biotechnology, China) and rinsing in PBS, bound antibodies were visualized by reaction with 3,3′diaminobenzidine (DAB). The tissues were counterstained with hematoxylin. Staining of Sox2 (Santa Cruz Biotechnology, USA) and Oct4 (Santa Cruz Biotechnology, USA) was done as described above.
Tumorosphere cells and tumorosphere-derived differentiated cells in cocultures were seeded on poly-D-lysine/laminin-coated coverslips (BD Biosciences, USA). The tumor cells were fixed in 4% paraformaldehyde in PBS for 6 min at room temperature, followed by two brief rinses with PBS. Fixed cells were permeabilized by incubation (room temperature) in 0.02% (v/v) Triton X-100 in PBS for 6 min. The cells were then briefly washed three times with PBS and stained using the antibodies and technique described above for tissue sections, the number of Nanog-positive cells in 300 cells were counted under light microscopy.
Semiquantitative reverse transcription PCR of Nanog, Oct4 and Sox2
Total RNA of tumorospheres and its differentiated cells or xenograft tumors was purified with TRIzol reagent (Invitrogen, USA) and reverse transcribed with a reverse transcription kit (Invitrogen, USA). We used 2 μl of each reaction for PCR in 1 μl of sense and antisense primers (Table 1) , and 1 μl of β-actin primer, 2.5 μl of 25 mmol/L MgCl 2 , 1 μl of deoxynucleotide triphosphates (100 mM), 2.5 μl of 10× PCR buffer, 5 units of Taq DNA polymerase and 14 μl of double-distilled water in a 25 μl reaction volume. The cycling protocol was: 4 min at 94°C; 20 cycles of 94°C for 50 s, 59°C for 1 min, 72°C for 50 s; and a final extension step at 72°C for 10 min. PCR products (1 μl) were electrophoresed in 1.5% (w/v) agarose gels and the gray scale ratio of PCR products was calculated.
Tumorosphere and xenograft tumor proliferation assays Tumorosphere cells or cells from digested xenograft tumors were plated at a density of 1,000 cells/well in 96-well microwell plates in 0.1 ml of SFM supplemented with growth factors. Cell proliferation assays were done at 24 h post-plating using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetr-azolium bromide-based Colorimetric Assay Cell Proliferation Kit 1 (Roche, USA). Quantification of viable cells was done by measurement of UV absorption at 575 nm with a Versamax microplate reader.
Implantation of tumorosphere and tumorosphere-derived differentiated cells into nude mice Tumorospheres and tumorosphere-derived differentiated cells from 21 ESCC patients were dissociated in nonenzymatic cell dissociation solution (Sigma) then washed with serum-free Hank's Balanced Salt Solution (HBSS). The cells were then suspended in a 1:1 (v/v) mixture of serum-free DMEM/F12 and Matrigel™, followed by subcutaneous injection of 1 × 10 5 cells into the right (differentiated cells) or left (tumorosphere cells) mid-abdominal area using a 23-gauge needle. Animals underwent autopsy at 28 days post-cell implantation and a straight ruler was used to assess tumor growth. The tumor volume (V) was calculated as:
where L is length and W is width. Visible tumors were excised for histological examination. Harvested tissues were fixed in phosphate-buffered 10% formalin (pH 7.2), embedded in paraffin, cut into 4 μm thick sections and stained with Nanog-specific antibodies as described above.
Cancer cell apoptosis assay
For quantitative analysis of apoptosis, xenograft tumors were trypsinized as described above, washed once in ice-cold PBS, and at least 400 cells were incubated with annexin-V-fluoroescein/PI (Boehringer Mannheim, USA) in calcium-containing Hepes buffer (pH 7.0); then analyzed immediately with a FAC-Scan machine (BD, USA).
Statistical analysis
We used independent-sample t-test to identify significant changes in transcription factor expression between the ESCC and EM samples. We used the χ 2 test determine whether there was significant variation in the frequency of transcription factor expression between the ESCC and EM samples. The level of statistically significant difference was set at P ≤ 0.05. SPSS software for PC (version 13.0 for Windows, SPSS, Inc., USA)
